carcinogenic agent - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	carcinogenic agent	go back to main search page
Accession:	CHEBI:50903	browse the term
Definition:	A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
Synonyms:	related_synonym:	agente carcinogeno; cancerigene; cancerogene; carcinogen; carcinogene; carcinogenic agents; carcinogeno; carcinogens

show annotations for term's descendants Sort by:
Rat (18507) Mouse (19706) Human (22899) Chinchilla (0) Bonobo (0) Dog (31) Squirrel (0) Pig (251) Green Monkey (0) Naked Mole-rat (0) All
Genes (251)

1,3-benzothiazole-2-thiol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thyroid peroxidase

decreases activity

captax results in decreased activity of TPO protein

PMID:23959146 PMID:25953703

NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208

2,3-dimethoxynaphthalene-1,4-dione

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; 2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [TNF protein results in increased expression of HIF1A protein]

NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845

G

tumor necrosis factor

multiple interactions

2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [TNF protein results in increased expression of HIF1A protein]

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

thyroid peroxidase

decreases activity

2,3-dimethoxy-1,4-naphthoquinone results in decreased activity of TPO protein

NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208

6-propyl-2-thiouracil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thyroid peroxidase

decreases activity

Propylthiouracil results in decreased activity of TPO protein

NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208

7,12-dimethyltetraphene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; [Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein

NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775

acrylamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcitonin-related polypeptide beta

increases expression

Acrylamide results in increased expression of CALCA protein

NCBI chr 2:44,043,135...44,048,651

G

interleukin 6

increases expression

Acrylamide results in increased expression of IL6 protein

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

interleukin-1 beta-like

increases expression

Acrylamide results in increased expression of IL1B protein

G

tachykinin precursor 1

increases expression

Acrylamide results in increased expression of TAC1 protein modified form

NCBI chr 9:77,197,403...77,206,529
Ensembl chr 9:77,197,536...77,206,523

G

tumor necrosis factor

increases expression

Acrylamide results in increased expression of TNF protein

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

vasoactive intestinal peptide

increases expression

Acrylamide results in increased expression of VIP protein

NCBI chr 1:13,611,786...13,620,250
Ensembl chr 1:13,611,311...13,620,269

aristolochic acid A

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 5-lipoxygenase activating protein

increases expression
multiple interactions

aristolochic acid I results in increased expression of ALOX5AP protein
MK-886 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein]; U 0126 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein]

NCBI chr11:7,371,328...7,438,111
Ensembl chr11:7,411,644...7,438,108

G

caspase 3

multiple interactions

aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein; MK-886 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein]

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

leukotriene C4 synthase

decreases expression

aristolochic acid I results in decreased expression of LTC4S protein

NCBI chr 2:78,799,446...78,802,281
Ensembl chr 2:78,799,449...78,802,285

G

mitogen-activated protein kinase 1

multiple interactions

aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK1 protein]

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 3

multiple interactions

aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [aristolochic acid I results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

G

microsomal glutathione S-transferase 3

increases expression
multiple interactions

aristolochic acid I results in increased expression of MGST3 protein
U 0126 inhibits the reaction [aristolochic acid I results in increased expression of MGST3 protein]

NCBI chr 4:85,069,603...85,095,022
Ensembl chr 4:85,069,607...85,094,981

aspartame

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamyl aminopeptidase

multiple interactions
increases hydrolysis

1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; amastatin inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; Calcium Chloride promotes the reaction [ENPEP protein results in increased hydrolysis of Aspartame]

NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510

benzo[a]pyrene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

multiple interactions

Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein]; Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Benzo(a)pyrene results in decreased expression of and results in decreased secretion of ADIPOQ protein

NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646

G

adiponectin receptor 1

decreases expression

Benzo(a)pyrene results in decreased expression of ADIPOR1 protein

NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686

G

adiponectin receptor 2

decreases expression

Benzo(a)pyrene results in decreased expression of ADIPOR2 protein

NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235

G

activating transcription factor 4

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of ATF4 protein]

NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368

G

activating transcription factor 6

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of ATF6 protein]

NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304

G

BCL2 associated X, apoptosis regulator

increases expression

Benzo(a)pyrene results in increased expression of BAX protein

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

decreases expression

Benzo(a)pyrene results in decreased expression of BCL2 protein

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

BCL2 like 1

decreases expression
multiple interactions

Benzo(a)pyrene results in decreased expression of BCL2L1 protein
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2L1 protein]

NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694

G

cyclin B1

decreases expression

Benzo(a)pyrene results in decreased expression of CCNB1 protein

NCBI chr16:47,338,239...47,348,385
Ensembl chr16:47,338,110...47,348,377

G

claudin 1

decreases expression
multiple interactions

Benzo(a)pyrene results in decreased expression of CLDN1 protein
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of CLDN1 protein]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of CLDN1 protein]

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

claudin 3

decreases expression
multiple interactions

Benzo(a)pyrene results in decreased expression of CLDN3 protein
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of CLDN3 protein]

NCBI chr 3:11,019,073...11,020,102
Ensembl chr 3:11,019,073...11,020,102

G

cytochrome P450 19A3

multiple interactions

Benzo(a)pyrene inhibits the reaction [ADIPOQ protein results in increased expression of CYP19A1 protein]

NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899

G

cytochrome P450 family 1 subfamily A member 1

increases expression
multiple interactions

Benzo(a)pyrene results in increased expression of CYP1A1 protein
7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; [Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein

PMID:11042205 PMID:18636242

NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775

G

DNA damage inducible transcript 3

increases expression
multiple interactions

Benzo(a)pyrene results in increased expression of DDIT3 protein
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of DDIT3 protein]

NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

Benzo(a)pyrene results in increased phosphorylation of EIF2S1 protein

NCBI chr 7:91,085,025...91,109,835
Ensembl chr 7:91,085,335...91,109,827

G

endoplasmic reticulum to nucleus signaling 1

increases phosphorylation
multiple interactions

Benzo(a)pyrene results in increased phosphorylation of ERN1 protein
4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of ERN1 protein]

NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284

G

H2A.X variant histone

increases expression

Benzo(a)pyrene results in increased expression of H2AX protein

NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Benzo(a)pyrene results in increased expression of HSPA5 protein]

NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894

G

lysosomal associated membrane protein 2

multiple interactions
decreases expression

bafilomycin A1 inhibits the reaction [Benzo(a)pyrene results in decreased expression of LAMP2 protein]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of LAMP2 protein]

NCBI chr X:98,586,718...98,623,939
Ensembl chr X:98,556,710...98,623,940

G

microtubule associated protein 1 light chain 3 beta

decreases lipidation
multiple interactions

Benzo(a)pyrene results in decreased lipidation of MAP1LC3B protein
bafilomycin A1 inhibits the reaction [Benzo(a)pyrene results in decreased lipidation of MAP1LC3B protein]; Benzo(a)pyrene promotes the reaction [3-methyladenine results in decreased lipidation of MAP1LC3B protein]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased lipidation of MAP1LC3B protein]

NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069

G

NFE2 like bZIP transcription factor 2

decreases expression

Benzo(a)pyrene results in decreased expression of NFE2L2 protein

NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183

G

occludin

decreases expression
multiple interactions

Benzo(a)pyrene results in decreased expression of OCLN protein
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of OCLN protein]

NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033

G

proliferating cell nuclear antigen

decreases expression

Benzo(a)pyrene results in decreased expression of PCNA protein

NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744

G

tight junction protein 1

decreases expression
multiple interactions

Benzo(a)pyrene results in decreased expression of TJP1 protein
4-phenylbutyric acid promotes the reaction [Benzo(a)pyrene results in decreased expression of TJP1 protein]

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

tight junction protein 2

decreases expression

Benzo(a)pyrene results in decreased expression of TJP2 protein

NCBI chr 1:222,474,518...222,612,989
Ensembl chr 1:222,474,639...222,612,983

bis(2-chloroethyl) sulfide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenomedullin

increases expression

Mustard Gas results in increased expression of ADM mRNA

NCBI chr 2:49,229,223...49,231,521
Ensembl chr 2:49,229,223...49,231,866

G

allograft inflammatory factor 1

increases expression

Mustard Gas results in increased expression of AIF1 mRNA

NCBI chr 7:23,711,752...23,731,191
Ensembl chr 7:23,726,787...23,731,671

G

alveolar macrophage-derived chemotactic factor-II

increases expression

Mustard Gas results in increased expression of CXCL5 mRNA

NCBI chr 8:70,008,225...70,010,360
Ensembl chr 8:70,008,162...70,010,358

G

alanyl aminopeptidase, membrane

increases expression

Mustard Gas results in increased expression of ANPEP mRNA

NCBI chr 7:55,351,081...55,373,856
Ensembl chr 7:55,351,087...55,373,881

G

annexin A1

increases expression

Mustard Gas results in increased expression of ANXA1 mRNA

NCBI chr 1:226,414,200...226,431,963
Ensembl chr 1:226,414,306...226,432,279

G

arginase 1

increases expression

Mustard Gas results in increased expression of ARG1 mRNA

NCBI chr 1:32,006,035...32,028,983
Ensembl chr 1:32,006,046...32,028,988

G

activating transcription factor 2

affects expression

Mustard Gas affects the expression of ATF2 mRNA

NCBI chr15:80,984,969...81,076,573
Ensembl chr15:80,985,126...81,081,014

G

BCL2 apoptosis regulator

decreases expression

Mustard Gas results in decreased expression of BCL2 protein

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

baculoviral IAP repeat containing 6

increases expression

Mustard Gas results in increased expression of BIRC6 mRNA

NCBI chr 3:107,012,967...107,269,370
Ensembl chr 3:107,012,986...107,269,477

G

bone morphogenetic protein 5

decreases expression

Mustard Gas results in decreased expression of BMP5 mRNA

NCBI chr 7:25,344,924...25,468,430
Ensembl chr 7:25,344,822...25,470,470

G

complement C2

increases expression

Mustard Gas results in increased expression of C2 mRNA

NCBI chr 7:24,020,590...24,034,042
Ensembl chr 7:23,995,982...24,033,930

G

complement C3

increases expression

Mustard Gas results in increased expression of C3 mRNA

NCBI chr 2:72,431,470...72,471,622
Ensembl chr 2:72,431,212...72,472,228

G

complement C7

increases expression

Mustard Gas results in increased expression of C7 mRNA

NCBI chr16:25,846,860...25,902,707
Ensembl chr16:25,846,860...25,903,980

G

calpain small subunit 1

increases expression

Mustard Gas results in increased expression of CAPNS1 mRNA

NCBI chr 6:45,511,410...45,518,610
Ensembl chr 6:45,511,295...45,518,610

G

caspase 3

increases expression

Mustard Gas results in increased expression of CASP3 mRNA

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

C-C motif chemokine ligand 19

increases expression

Mustard Gas results in increased expression of CCL19 mRNA

NCBI chr10:32,110,366...32,112,529
Ensembl chr10:32,110,065...32,112,734

G

chemokine (C-C motif) ligand 2

increases expression

Mustard Gas results in increased expression of CCL2 mRNA

PMID:18988085 PMID:27617619

NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026

G

C-C motif chemokine ligand 5

increases expression

Mustard Gas results in increased expression of CCL5 mRNA

NCBI chr12:39,652,731...39,659,121
Ensembl chr12:39,648,598...39,659,118

G

cellular communication network factor 1

increases expression

Mustard Gas results in increased expression of CCN1 mRNA

NCBI chr 4:130,392,404...130,395,179
Ensembl chr 4:130,392,407...130,395,150

G

cellular communication network factor 2

increases expression

Mustard Gas results in increased expression of CCN2 mRNA

NCBI chr 1:31,674,398...31,677,697
Ensembl chr 1:31,674,394...31,677,691

G

C-C motif chemokine receptor 1

increases expression

Mustard Gas results in increased expression of CCR1 mRNA

NCBI chr13:29,227,218...29,233,862
Ensembl chr13:29,227,222...29,233,960

G

C-C motif chemokine receptor 5

decreases expression

Mustard Gas results in decreased expression of CCR5 mRNA

NCBI chr13:29,382,383...29,387,902
Ensembl chr13:29,383,303...29,387,895

G

cyclin dependent kinase inhibitor 1A

increases expression

Mustard Gas results in increased expression of CDKN1A mRNA

NCBI chr 7:32,354,776...32,363,771
Ensembl chr 7:32,359,455...32,363,761

G

complement factor B

increases expression

Mustard Gas results in increased expression of BF mRNA

NCBI chr 7:24,034,077...24,040,523
Ensembl chr 7:24,033,740...24,041,179

G

claudin 1

decreases expression

Mustard Gas results in decreased expression of CLDN1 mRNA

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

clusterin

increases expression

Mustard Gas results in increased expression of CLU mRNA

NCBI chr14:11,336,585...11,352,569
Ensembl chr14:11,336,595...11,349,764

G

catenin alpha 3

decreases expression

Mustard Gas results in decreased expression of CTNNA3 mRNA

NCBI chr14:69,195,231...70,974,543
Ensembl chr14:69,195,961...70,938,204

G

chemokine (C-X-C motif) ligand 2

increases expression

Mustard Gas results in increased expression of CXCL2 mRNA

NCBI chr 8:70,157,253...70,159,145
Ensembl chr 8:70,157,214...70,159,138

G

C-X-C motif chemokine ligand 8

increases expression

Mustard Gas results in increased expression of CXCL8 mRNA

PMID:12481301 PMID:18988085 PMID:27617619

NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861

G

C-X-C motif chemokine receptor 4

increases expression

Mustard Gas results in increased expression of CXCR4 mRNA

NCBI chr15:15,663,652...15,666,706
Ensembl chr15:15,663,494...15,667,232

G

early growth response 1

increases expression

Mustard Gas results in increased expression of EGR1 mRNA

PMID:18988085 PMID:27617619

NCBI chr 2:140,440,829...140,445,302
Ensembl chr 2:140,441,421...140,445,296

G

EPH receptor A4

decreases expression

Mustard Gas results in decreased expression of EPHA4 mRNA

NCBI chr15:123,350,867...123,501,872
Ensembl chr15:123,352,816...123,503,126

G

F-box protein 32

decreases expression

Mustard Gas results in decreased expression of FBXO32 mRNA

NCBI chr 4:15,895,875...15,925,929
Ensembl chr 4:15,895,689...15,930,931

G

ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin)

increases expression

Mustard Gas results in increased expression of FCNB mRNA

NCBI chr 1:274,106,276...274,111,970
Ensembl chr 1:274,103,877...274,111,970

G

fibroblast growth factor 2

increases expression

Mustard Gas results in increased expression of FGF2 mRNA

NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,885...101,343,916

G

fibroblast growth factor receptor 2

decreases expression

Mustard Gas results in decreased expression of FGFR2 mRNA

NCBI chr14:131,183,095...131,285,001
Ensembl chr14:131,181,713...131,289,425

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Mustard Gas results in increased expression of FOS mRNA

PMID:18988085 PMID:27617619

NCBI chr 7:98,449,508...98,451,971
Ensembl chr 7:98,449,349...98,455,554

G

FXYD domain containing ion transport regulator 3

decreases expression

Mustard Gas results in decreased expression of FXYD3 mRNA

NCBI chr 6:44,647,771...44,654,377
Ensembl chr 6:44,647,466...44,654,374

G

growth arrest and DNA damage inducible alpha

increases expression

Mustard Gas results in increased expression of GADD45A mRNA

NCBI chr 6:144,940,702...144,944,089
Ensembl chr 6:144,940,697...144,944,089

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Mustard Gas results in increased expression of GAPDH mRNA

NCBI chr 5:64,129,678...64,135,194
Ensembl chr 5:64,129,679...64,133,991

G

guanylate cyclase 1 soluble subunit beta 1

increases expression

Mustard Gas results in increased expression of GUCY1B1 mRNA

NCBI chr 8:44,544,364...44,604,690
Ensembl chr 8:44,544,179...44,604,687

G

heparin binding EGF like growth factor

increases expression

Mustard Gas results in increased expression of HBEGF mRNA

NCBI chr 2:142,102,455...142,115,192
Ensembl chr 2:142,102,458...142,115,174

G

heme oxygenase 1

increases expression

Mustard Gas results in increased expression of HMOX1 mRNA

G

heat shock protein family A (Hsp70) member 1 like

increases expression

Mustard Gas results in increased expression of HSPA1L mRNA

NCBI chr 7:23,909,960...23,938,678
Ensembl chr 7:23,909,960...23,914,629

G

intercellular adhesion molecule 1

increases expression

Mustard Gas results in increased expression of ICAM1 mRNA

NCBI chr 2:69,097,136...69,107,722
Ensembl chr 2:69,097,122...69,108,205

G

insulin like growth factor 1

increases expression

Mustard Gas results in increased expression of IGF1 mRNA

NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033

G

insulin like growth factor binding protein 5

decreases expression

Mustard Gas results in decreased expression of IGFBP5 mRNA

NCBI chr15:118,861,816...118,877,787
Ensembl chr15:118,857,625...118,878,120

G

interleukin 1 receptor type 1

increases expression

Mustard Gas results in increased expression of IL1R1 mRNA

NCBI chr 3:52,192,912...52,334,734
Ensembl chr 3:52,192,915...52,288,485

G

interleukin 23 subunit alpha

decreases expression

Mustard Gas results in decreased expression of IL23A mRNA

NCBI chr 5:21,732,416...21,733,981
Ensembl chr 5:21,732,165...21,734,267

G

interleukin 4 receptor

decreases expression

Mustard Gas results in decreased expression of IL4R mRNA

NCBI chr 3:19,526,343...19,576,792
Ensembl chr 3:19,523,564...19,576,544

G

interleukin 6

increases expression

Mustard Gas results in increased expression of IL6 mRNA

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

inhibitor of carbonic anhydrase

decreases expression

Mustard Gas results in decreased expression of PICA mRNA

NCBI chr13:74,862,502...74,907,059

G

integrin subunit alpha 6

affects expression

Mustard Gas affects the expression of ITGA6 protein

NCBI chr15:78,504,108...78,591,779
Ensembl chr15:78,504,078...78,591,777

G

integrin subunit beta 2

increases expression

Mustard Gas results in increased expression of ITGB2 mRNA

NCBI chr13:207,514,281...207,544,108
Ensembl chr13:207,512,950...207,544,107

G

integrin subunit beta 4

affects expression

Mustard Gas affects the expression of ITGB4 protein

NCBI chr12:5,651,292...5,685,601
Ensembl chr12:5,651,292...5,685,611

G

laminin subunit gamma 2

decreases expression

Mustard Gas results in decreased expression of LAMC2 protein

NCBI chr 9:124,427,545...124,499,672
Ensembl chr 9:124,435,807...124,495,351

G

lactate dehydrogenase A

increases expression

Mustard Gas results in increased expression of LDHA mRNA

NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715

G

platelet factor 4

increases expression

Mustard Gas results in increased expression of PF4 mRNA

G

interleukin-1 beta-like

increases expression

Mustard Gas results in increased expression of IL1B mRNA

G

lactotransferrin

increases expression

Mustard Gas results in increased expression of PLF mRNA

NCBI chr13:29,413,886...29,445,751
Ensembl chr13:29,413,886...29,445,739

G

matrix metallopeptidase 9

increases expression

Mustard Gas results in increased expression of MMP9 mRNA

NCBI chr17:48,179,690...48,186,782
Ensembl chr17:48,179,671...48,186,788

G

metallothionein 3

decreases expression

Mustard Gas results in decreased expression of MT3 mRNA

NCBI chr 6:18,634,735...18,636,134
Ensembl chr 6:18,634,261...18,636,131

G

MYC proto-oncogene, bHLH transcription factor

increases expression

Mustard Gas results in increased expression of MYC mRNA

NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078

G

natriuretic peptide B

increases expression

Mustard Gas results in increased expression of NPPB mRNA

NCBI chr 6:71,930,374...71,931,843
Ensembl chr 6:71,930,382...71,932,254

G

nuclear receptor subfamily 2 group F member 2

increases expression

Mustard Gas results in increased expression of NR2F2 mRNA

NCBI chr 7:83,076,119...83,090,250
Ensembl chr 7:83,076,124...83,090,535

G

nuclear receptor subfamily 4 group A member 3

increases expression

Mustard Gas results in increased expression of NR4A3 mRNA

NCBI chr 1:241,569,867...241,611,735
Ensembl chr 1:241,570,010...241,611,727

G

oxidative stress induced growth inhibitor 1

increases expression

Mustard Gas results in increased expression of OSGIN1 mRNA

NCBI chr 6:4,642,762...4,656,113
Ensembl chr 6:4,642,764...4,653,487

G

proliferating cell nuclear antigen

increases expression

Mustard Gas results in increased expression of PCNA protein

NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744

G

platelet derived growth factor receptor alpha

increases expression

Mustard Gas results in increased expression of PDGFRA mRNA

NCBI chr 8:40,966,568...41,021,440
Ensembl chr 8:40,967,493...41,021,441

G

plasminogen activator, urokinase

increases expression

Mustard Gas results in increased expression of PLAU mRNA

NCBI chr14:76,629,313...76,635,173
Ensembl chr14:76,629,299...76,635,172

G

plasminogen activator, urokinase receptor

increases expression

Mustard Gas results in increased expression of PLAUR mRNA

NCBI chr 6:50,489,773...50,505,453
Ensembl chr 6:50,489,777...50,505,418

G

POU class 2 homeobox 3

decreases expression

Mustard Gas results in decreased expression of POU2F3 mRNA

NCBI chr 9:47,376,852...47,458,265
Ensembl chr 9:47,376,750...47,460,165

G

PPARG related coactivator 1

increases expression

Mustard Gas results in increased expression of PPRC1 mRNA

NCBI chr14:113,137,012...113,152,828
Ensembl chr14:113,137,037...113,152,831

G

Rap guanine nucleotide exchange factor 4

decreases expression

Mustard Gas results in decreased expression of RAPGEF4 mRNA

NCBI chr15:78,773,270...79,094,490
Ensembl chr15:78,773,266...79,095,040

G

Rh family B glycoprotein

decreases expression

Mustard Gas results in decreased expression of RHBG mRNA

NCBI chr 4:93,694,259...93,708,055
Ensembl chr 4:93,694,266...93,707,865

G

scavenger receptor class B member 2

increases expression

Mustard Gas results in increased expression of SCARB2 mRNA

NCBI chr 8:71,838,395...71,910,461
Ensembl chr 8:71,838,397...71,940,607

G

selectin E

increases expression

Mustard Gas results in increased expression of SELE mRNA

NCBI chr 4:81,289,061...81,299,657

G

serpin family E member 1

increases expression

Mustard Gas results in increased expression of SERPINE1 mRNA

NCBI chr 3:8,863,738...8,871,572
Ensembl chr 3:8,863,695...8,871,547

G

hyaluronan synthase 2

increases expression

Mustard Gas results in increased expression of SHAS2 mRNA

NCBI chr 4:17,583,154...17,613,524
Ensembl chr 4:17,596,492...17,615,480

G

solute carrier family 5 member 1

decreases expression

Mustard Gas results in decreased expression of SLC5A1 mRNA

NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841

G

superoxide dismutase 2

increases expression

Mustard Gas results in increased expression of SOD2 mRNA

NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560

G

secreted phosphoprotein 1

increases expression

Mustard Gas results in increased expression of SPP1 mRNA

NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340

G

thromboxane A synthase 1

increases expression

Mustard Gas results in increased expression of TBXAS1 mRNA

NCBI chr18:9,717,291...9,886,699
Ensembl chr18:9,717,294...9,886,681

G

TIMP metallopeptidase inhibitor 1

increases expression

Mustard Gas results in increased expression of TIMP1 mRNA

NCBI chr X:42,103,251...42,106,289
Ensembl chr X:42,102,172...42,106,296

G

toll like receptor 2

increases expression

Mustard Gas results in increased expression of TLR2 mRNA

NCBI chr 8:75,416,257...75,428,370
Ensembl chr 8:75,411,993...75,428,330

G

toll like receptor 4

increases expression

Mustard Gas results in increased expression of TLR4 mRNA

NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970

G

tenascin C

increases expression

Mustard Gas results in increased expression of TNC mRNA

NCBI chr 1:255,533,235...255,630,381
Ensembl chr 1:255,533,238...255,630,376

G

tumor necrosis factor

increases expression

Mustard Gas results in increased expression of TNF mRNA

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

tenascin XB

decreases expression

Mustard Gas results in decreased expression of TNXB mRNA

NCBI chr 7:24,088,873...24,155,815
Ensembl chr 7:24,088,873...24,150,596

G

tumor protein p53

increases expression

Mustard Gas results in increased expression of TP53 protein

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

G

thioredoxin

increases expression

Mustard Gas results in increased expression of TXN mRNA

NCBI chr 1:251,264,180...251,278,000
Ensembl chr 1:251,263,175...251,277,988

G

TYRO3 protein tyrosine kinase

decreases expression

Mustard Gas results in decreased expression of TYRO3 mRNA

NCBI chr 1:129,811,540...129,829,395
Ensembl chr 1:129,811,544...129,829,014

G

UDP-glucose pyrophosphorylase 2

increases expression

Mustard Gas results in increased expression of UGP2 mRNA

NCBI chr 3:77,975,450...78,032,471
Ensembl chr 3:77,975,441...78,031,703

G

vav guanine nucleotide exchange factor 3

decreases expression

Mustard Gas results in decreased expression of VAV3 mRNA

NCBI chr 4:111,825,071...112,202,833
Ensembl chr 4:111,824,896...112,202,825

G

vascular cell adhesion molecule 1

increases expression

Mustard Gas results in increased expression of VCAM1 mRNA

NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon

increases expression

Mustard Gas results in increased expression of YWHAE mRNA

NCBI chr12:47,601,133...47,645,327
Ensembl chr12:47,600,745...47,645,301

cadmium nitrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CD14 molecule

affects expression

cadmium nitrate affects the expression of CD14 mRNA

NCBI chr 2:142,348,036...142,349,686
Ensembl chr 2:142,346,360...142,349,581

G

C-X-C motif chemokine ligand 8

affects expression
affects secretion

cadmium nitrate affects the expression of CXCL8 mRNA
cadmium nitrate affects the secretion of CXCL8 protein

NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861

G

defensin beta 1

increases expression

cadmium nitrate results in increased expression of DEFB1 mRNA

G

interferon beta 1

increases expression

cadmium nitrate results in increased expression of IFNB1 mRNA

NCBI chr 1:201,850,935...201,851,495
Ensembl chr 1:201,850,935...201,851,495

G

interleukin 18

increases expression

cadmium nitrate results in increased expression of IL18 mRNA

NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219

G

interleukin 6

increases expression

cadmium nitrate results in increased expression of IL6 mRNA

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

interleukin-1 beta-like

increases expression

cadmium nitrate results in increased expression of IL1B mRNA

G

mitogen-activated protein kinase 14

affects expression

cadmium nitrate affects the expression of MAPK14 mRNA

NCBI chr 7:31,791,398...31,861,544
Ensembl chr 7:31,790,877...31,862,031

G

mitogen-activated protein kinase 8

increases expression

cadmium nitrate results in increased expression of MAPK8 mRNA

NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874

G

MYD88 innate immune signal transduction adaptor

affects expression

cadmium nitrate affects the expression of MYD88 mRNA

NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109

G

nuclear factor kappa B subunit 1

affects expression

cadmium nitrate affects the expression of NFKB1 mRNA

NCBI chr 8:118,391,010...118,478,927
Ensembl chr 8:118,390,638...118,506,691

G

RELA proto-oncogene, NF-kB subunit

increases expression

cadmium nitrate results in increased expression of RELA mRNA

NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469

G

suppressor of cytokine signaling 1

decreases expression

cadmium nitrate results in decreased expression of SOCS1 mRNA

NCBI chr 3:31,879,143...31,883,041
Ensembl chr 3:31,881,225...31,884,967

G

signal transducer and activator of transcription 3

decreases expression

cadmium nitrate results in decreased expression of STAT3 mRNA

NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,992

G

toll like receptor 4

affects expression

cadmium nitrate affects the expression of TLR4 mRNA

NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970

G

toll like receptor 5

increases expression

cadmium nitrate results in increased expression of TLR5 mRNA

NCBI chr10:19,387,666...19,410,024
Ensembl chr10:19,387,666...19,410,024

G

tumor necrosis factor

increases expression

cadmium nitrate results in increased expression of TNF mRNA

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

chlortetracycline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier organic anion transporter family member 1A2

multiple interactions
increases uptake

Chlortetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]

NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730

cyclophosphamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Panobinostat inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

multiple interactions
decreases expression

Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

H2A.X variant histone

multiple interactions
increases expression

Panobinostat inhibits the reaction [Cyclophosphamide results in increased expression of H2AX protein]

NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084

G

Nanog homeobox

multiple interactions

[Panobinostat co-treated with Cyclophosphamide] results in increased expression of NANOG mRNA

NCBI chr 5:62,931,642...62,939,086
Ensembl chr 5:62,932,382...62,939,082

G

POU class 5 homeobox 1

multiple interactions
decreases expression

Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of POU5F1 mRNA]

NCBI chr 7:23,564,654...23,570,691

G

superoxide dismutase 1

multiple interactions
decreases expression

Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of SOD1 mRNA]

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

SRY-box transcription factor 2

decreases expression
multiple interactions

Cyclophosphamide results in decreased expression of SOX2 mRNA
Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of SOX2 mRNA]

NCBI chr13:119,668,476...119,669,435
Ensembl chr13:119,668,476...119,669,435

cyclosporin A

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions
affects localization

Vitamin E inhibits the reaction [Cyclosporine affects the localization of BAX protein]

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

caspase 6

multiple interactions
increases expression

Vitamin E inhibits the reaction [Cyclosporine results in increased expression of CASP6 mRNA]

NCBI chr 8:112,519,450...112,534,315
Ensembl chr 8:112,520,629...112,537,045

G

cytochrome c, somatic

multiple interactions
affects localization

Vitamin E inhibits the reaction [Cyclosporine affects the localization of CYCS protein]

NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866

G

endothelin 1

increases secretion

Cyclosporine results in increased secretion of EDN1 protein

NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348

G

FYVE, RhoGEF and PH domain containing 4

multiple interactions
increases expression

Vitamin E inhibits the reaction [Cyclosporine results in increased expression of DNM1L protein]

NCBI chr 5:41,571,054...41,636,058
Ensembl chr 5:41,570,282...41,636,028

G

mitofusin 2

multiple interactions
decreases expression

Vitamin E inhibits the reaction [Cyclosporine results in decreased expression of MFN2 protein]

NCBI chr 6:72,026,512...72,056,439
Ensembl chr 6:72,028,499...72,056,438

G

nitric oxide synthase 3

decreases expression

Cyclosporine results in decreased expression of NOS3 protein

NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943

G

OPA1 mitochondrial dynamin like GTPase

decreases expression
multiple interactions

Cyclosporine results in decreased expression of OPA1 protein
Vitamin E inhibits the reaction [Cyclosporine results in decreased expression of OPA1 protein]

NCBI chr13:130,624,771...130,718,345
Ensembl chr13:130,624,796...130,719,083

G

Rac family small GTPase 1

affects localization

Cyclosporine affects the localization of RAC1 protein

NCBI chr 3:4,781,776...4,803,510
Ensembl chr 3:4,781,780...4,803,543

G

solute carrier family 2 member 1

decreases response to substance
multiple interactions
increases expression

SLC2A1 protein results in decreased susceptibility to Cyclosporine
Amiloride promotes the reaction [Cyclosporine results in increased expression of SLC2A1 mRNA]; Phloretin promotes the reaction [Cyclosporine results in increased expression of SLC2A1 mRNA]; Phloretin promotes the reaction [Cyclosporine results in increased expression of SLC2A1 protein]
Cyclosporine results in increased expression of SLC2A1 mRNA; Cyclosporine results in increased expression of SLC2A1 protein

NCBI chr 6:168,535,398...168,561,170
Ensembl chr 6:168,535,440...168,560,867

doxorubicin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gap junction protein alpha 1

decreases expression

Doxorubicin results in decreased expression of GJA1 protein

NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156

G

heat shock protein family A (Hsp70) member 1 like

increases expression

Doxorubicin results in increased expression of HSPA1A protein

NCBI chr 7:23,909,960...23,938,678
Ensembl chr 7:23,909,960...23,914,629

G

matrix metallopeptidase 1

increases activity
increases expression

Doxorubicin results in increased activity of MMP1 protein
Doxorubicin results in increased expression of MMP1 mRNA

NCBI chr 9:33,411,738...33,420,205
Ensembl chr 9:33,411,065...33,420,076

G

matrix metallopeptidase 14

increases expression
increases activity

Doxorubicin results in increased expression of MMP14 mRNA
Doxorubicin results in increased activity of MMP14 protein

NCBI chr 7:76,174,502...76,185,931
Ensembl chr 7:76,172,971...76,185,928

G

matrix metallopeptidase 2

increases expression
increases activity

Doxorubicin results in increased expression of MMP2 mRNA
Doxorubicin results in increased activity of MMP2 protein

NCBI chr 6:30,059,247...30,087,031
Ensembl chr 6:30,058,595...30,086,982

G

matrix metallopeptidase 9

increases expression
increases activity

Doxorubicin results in increased expression of MMP9 mRNA
Doxorubicin results in increased activity of MMP9 protein

NCBI chr17:48,179,690...48,186,782
Ensembl chr17:48,179,671...48,186,788

G

tumor necrosis factor

decreases expression

Doxorubicin results in decreased expression of TNF mRNA

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

troponin T2, cardiac type

decreases expression

Doxorubicin results in decreased expression of TNNT2 protein

NCBI chr10:23,749,528...23,759,696
Ensembl chr10:23,749,335...23,763,396

doxycycline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier organic anion transporter family member 1A2

increases uptake
multiple interactions

SLCO1A2 protein results in increased uptake of Doxycycline
Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]

NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730

fumonisin B1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

advanced glycosylation end-product specific receptor

increases expression

fumonisin B1 results in increased expression of AGER mRNA

NCBI chr 7:24,218,116...24,221,162
Ensembl chr 7:24,218,120...24,221,162

G

apoptotic peptidase activating factor 1

multiple interactions
increases expression

fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein]
fumonisin B1 results in increased expression of APAF1 mRNA; fumonisin B1 results in increased expression of APAF1 protein

NCBI chr 5:85,166,616...85,258,751
Ensembl chr 5:85,166,628...85,258,364

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]
fumonisin B1 results in increased expression of BAX mRNA; fumonisin B1 results in increased expression of BAX protein

PMID:33905761 PMID:36397609

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

decreases expression
multiple interactions

fumonisin B1 results in decreased expression of BCL2 mRNA; fumonisin B1 results in decreased expression of BCL2 protein
[Acetylcysteine co-treated with fumonisin B1 co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of BCL2 protein; [fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone co-treated with deoxynivalenol] results in decreased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]; fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; fumonisin B1 inhibits the reaction [Zearalenone inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Zearalenone inhibits the reaction [fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]]; Zearalenone inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]

PMID:29109043 PMID:33905761 PMID:36397609

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

caspase 1, apoptosis-related cysteine peptidase

multiple interactions

N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP1 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP1 protein]

NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328

G

caspase 10

multiple interactions
increases expression

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP10 mRNA]

NCBI chr15:104,858,082...104,895,941
Ensembl chr15:104,858,100...104,894,933

G

caspase 3

multiple interactions
increases expression

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; [fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]
fumonisin B1 results in increased expression of CASP3 mRNA; fumonisin B1 results in increased expression of CASP3 protein; fumonisin B1 results in increased expression of CASP3 protein modified form

PMID:29109043 PMID:32198028 PMID:33905761 PMID:36397609

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

caspase 8

multiple interactions
increases expression

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of CASP8 mRNA]

NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468

G

caspase 9

multiple interactions
increases expression

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]
fumonisin B1 results in increased expression of CASP9 mRNA; fumonisin B1 results in increased expression of CASP9 protein; fumonisin B1 results in increased expression of CASP9 protein modified form

PMID:33905761 PMID:36397609

NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007

G

chemokine (C-C motif) ligand 2

multiple interactions
decreases expression
increases expression

[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]
fumonisin B1 results in decreased expression of CCL2 mRNA
fumonisin B1 metabolite results in increased expression of CCL2 mRNA; fumonisin B1 results in increased expression of CCL2 mRNA

PMID:23688591 PMID:30708112

NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026

G

C-C motif chemokine ligand 20

increases expression
multiple interactions

fumonisin B1 results in increased expression of CCL20 mRNA
fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]

NCBI chr15:129,172,743...129,176,069

G

component of inhibitor of nuclear factor kappa B kinase complex

increases expression

fumonisin B1 results in increased expression of CHUK mRNA

NCBI chr14:111,316,178...111,351,669
Ensembl chr14:111,315,141...111,351,868

G

claudin 1

decreases expression

fumonisin B1 results in decreased expression of CLDN1 mRNA; fumonisin B1 results in decreased expression of CLDN1 protein

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

C-X-C motif chemokine ligand 8

multiple interactions
increases expression

[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]
fumonisin B1 results in increased expression of CXCL8 mRNA

PMID:23688591 PMID:30708112

NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861

G

cytochrome c, somatic

multiple interactions

[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CYCS mRNA]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]

PMID:29109043 PMID:36397609

NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866

G

gasdermin D

multiple interactions

belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of GSDMD protein]

NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271

G

glutathione-disulfide reductase

multiple interactions

Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]

NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984

G

hepatitis A virus cellular receptor 1

multiple interactions

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of HAVCR1 mRNA

NCBI chr16:66,162,318...66,208,868

G

interferon gamma

decreases expression

fumonisin B1 metabolite results in decreased expression of IFNG protein

NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670

G

interleukin 17A

multiple interactions

fumonisin B1 inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]

NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153

G

interleukin 18

multiple interactions

belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL18 protein]

NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219

G

interleukin 1 alpha

multiple interactions
increases expression
decreases expression

[deoxynivalenol co-treated with fumonisin B1] results in decreased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA
fumonisin B1 results in increased expression of IL1A mRNA
fumonisin B1 results in decreased expression of IL1A mRNA

NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119

G

interleukin 6

multiple interactions
decreases expression
increases expression

[deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in decreased expression of IL6 mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA
fumonisin B1 results in decreased expression of IL6 mRNA
fumonisin B1 results in increased expression of IL6 mRNA

PMID:23688591 PMID:30708112

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

lipocalin 2

multiple interactions

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of LCN2 mRNA

NCBI chr 1:268,609,975...268,614,651
Ensembl chr 1:268,609,887...268,614,644

G

interleukin-1 beta-like

increases expression
multiple interactions

fumonisin B1 results in increased expression of IL1B mRNA
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B mRNA]; belnacasan inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of IL1B protein]

PMID:23688591 PMID:36309173

G

mitogen-activated protein kinase kinase kinase 14

increases expression

fumonisin B1 results in increased expression of MAP3K14 mRNA

NCBI chr12:18,142,899...18,182,931
Ensembl chr12:18,142,952...18,182,928

G

mitogen-activated protein kinase 1

increases phosphorylation

fumonisin B1 results in increased phosphorylation of MAPK1 protein

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 10

increases expression
multiple interactions

fumonisin B1 results in increased expression of MAPK10 mRNA
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK10 mRNA]

NCBI chr 8:132,445,818...132,751,575
Ensembl chr 8:132,298,299...132,776,820

G

mitogen-activated protein kinase 3

increases phosphorylation

fumonisin B1 results in increased phosphorylation of MAPK3 protein

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

G

mitogen-activated protein kinase 8

increases expression
multiple interactions

fumonisin B1 results in increased expression of MAPK8 mRNA; fumonisin B1 results in increased expression of MAPK8 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK8 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK8 protein]

NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874

G

mitogen-activated protein kinase 9

increases expression
multiple interactions

fumonisin B1 results in increased expression of MAPK9 mRNA
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of MAPK9 mRNA]

NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,376...78,399,100

G

mucin 1, cell surface associated

decreases expression

fumonisin B1 results in decreased expression of MUC1 mRNA

NCBI chr 4:94,626,317...94,631,194

G

mucin 2, oligomeric mucus/gel-forming

increases expression

fumonisin B1 results in increased expression of MUC2 mRNA

NCBI chr 2:689,363...719,542
Ensembl chr 2:689,364...710,330

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

fumonisin B1 results in increased expression of NFKB1 mRNA; fumonisin B1 results in increased expression of NFKB1 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of NFKB1 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [fumonisin B1 results in increased expression of NFKB1 protein]

NCBI chr 8:118,391,010...118,478,927
Ensembl chr 8:118,390,638...118,506,691

G

netrin 1

multiple interactions

fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of NTN1 mRNA]

NCBI chr12:54,089,444...54,292,191
Ensembl chr12:54,089,472...54,292,193

G

occludin

decreases expression

fumonisin B1 results in decreased expression of OCLN mRNA; fumonisin B1 results in decreased expression of OCLN protein

NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033

G

solute carrier family 15 member 1

increases expression

fumonisin B1 results in increased expression of SLC15A1 mRNA

NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933

G

solute carrier family 1 member 1

decreases expression

fumonisin B1 results in decreased expression of SLC1A1 mRNA

NCBI chr 1:217,366,493...217,441,643
Ensembl chr 1:217,366,499...217,441,674

G

solute carrier family 27 member 4

decreases expression

fumonisin B1 results in decreased expression of SLC27A4 mRNA

NCBI chr 1:268,773,792...268,788,208
Ensembl chr 1:268,773,806...268,788,731

G

solute carrier family 2 member 2

decreases expression

fumonisin B1 results in decreased expression of SLC2A2 mRNA

NCBI chr13:109,592,595...109,614,105
Ensembl chr13:109,587,258...109,638,510

G

solute carrier family 7 member 1

decreases expression

fumonisin B1 results in decreased expression of SLC7A1 mRNA

NCBI chr11:6,538,053...6,604,654
Ensembl chr11:6,538,045...6,604,658

G

solute carrier family 7 member 7

decreases expression

fumonisin B1 results in decreased expression of SLC7A7 mRNA

NCBI chr 7:76,195,774...76,235,406
Ensembl chr 7:76,198,256...76,235,402

G

secreted phosphoprotein 1

increases expression
multiple interactions

fumonisin B1 results in increased expression of SPP1 mRNA
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of SPP1 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of SPP1 mRNA]

NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340

G

tight junction protein 1

decreases expression

fumonisin B1 results in decreased expression of TJP1 mRNA; fumonisin B1 results in decreased expression of TJP1 protein

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

tumor necrosis factor

multiple interactions
increases expression

[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF protein; [deoxynivalenol co-treated with nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA
fumonisin B1 results in increased expression of TNF mRNA; fumonisin B1 results in increased expression of TNF protein

PMID:23688591 PMID:30708112 PMID:32198028

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

tumor protein p53

increases expression
multiple interactions

fumonisin B1 results in increased expression of TP53 mRNA
[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]]; fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

G

TNFRSF1A associated via death domain

increases expression

fumonisin B1 results in increased expression of TRADD mRNA

NCBI chr 6:27,797,594...27,804,654
Ensembl chr 6:27,797,607...27,804,423

G

TNF receptor associated factor 2

increases expression

fumonisin B1 results in increased expression of TRAF2 mRNA

hexachlorobenzene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

multiple interactions

Hexachlorobenzene inhibits the reaction [ADIPOQ protein results in increased secretion of Estradiol]; Hexachlorobenzene results in decreased expression of and results in decreased secretion of ADIPOQ protein

NCBI chr13:124,633,906...124,646,237
Ensembl chr13:124,633,685...124,646,646

G

adiponectin receptor 1

decreases expression

Hexachlorobenzene results in decreased expression of ADIPOR1 protein

NCBI chr10:24,907,491...24,923,540
Ensembl chr10:24,907,491...24,915,686

G

adiponectin receptor 2

decreases expression

Hexachlorobenzene results in decreased expression of ADIPOR2 protein

NCBI chr 5:68,755,789...68,807,247
Ensembl chr 5:68,755,811...68,807,235

G

cytochrome P450 family 11 subfamily A member 1

increases expression

Hexachlorobenzene results in increased expression of CYP11A1 protein

NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478

G

cytochrome P450 family 17 subfamily A member 1

decreases expression

Hexachlorobenzene results in decreased expression of CYP17A1 protein

NCBI chr14:113,805,616...113,820,445
Ensembl chr14:113,805,611...113,812,041

G

cytochrome P450 19A3

decreases expression

Hexachlorobenzene results in decreased expression of CYP19A1 protein

NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899

G

hydroxysteroid 17-beta dehydrogenase 1

decreases expression

Hexachlorobenzene results in decreased expression of HSD17B1 protein

NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,271,548

ochratoxin A

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation

ochratoxin A results in decreased phosphorylation of AKT1 protein

G

annexin A5

decreases expression

ochratoxin A results in decreased expression of ANXA5 mRNA

NCBI chr 8:102,387,833...102,420,868
Ensembl chr 8:102,388,103...102,425,750

G

apoptotic peptidase activating factor 1

increases expression
multiple interactions

ochratoxin A results in increased expression of APAF1 mRNA; ochratoxin A results in increased expression of APAF1 protein
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein]

NCBI chr 5:85,166,616...85,258,751
Ensembl chr 5:85,166,628...85,258,364

G

autophagy related 5

multiple interactions
increases expression

ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]
ochratoxin A results in increased expression of ATG5 protein

PMID:28699257 PMID:30287338

NCBI chr 1:72,343,950...72,520,402
Ensembl chr 1:72,270,799...72,520,396

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]
ochratoxin A results in increased expression of BAX mRNA; ochratoxin A results in increased expression of BAX protein

PMID:33905761 PMID:36397609

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

multiple interactions
decreases expression
affects expression

[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]
ochratoxin A results in decreased expression of BCL2 mRNA; ochratoxin A results in decreased expression of BCL2 protein

PMID:28528741 PMID:29080797 PMID:33905761 PMID:36397609

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

beclin 1

multiple interactions
increases expression

BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]
ochratoxin A results in increased expression of BECN1 protein

NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373

G

BRCA1 DNA repair associated

increases expression

ochratoxin A results in increased expression of BRCA1 protein

NCBI chr12:19,788,087...19,854,515
Ensembl chr12:19,786,020...19,854,668

G

caspase 1, apoptosis-related cysteine peptidase

multiple interactions

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]; ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein; Taurine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]

NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328

G

caspase 3

multiple interactions
increases expression
increases cleavage

3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]
ochratoxin A results in increased expression of CASP3 mRNA; ochratoxin A results in increased expression of CASP3 protein; ochratoxin A results in increased expression of CASP3 protein modified form

PMID:30287338 PMID:33905761 PMID:36397609

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

caspase 9

multiple interactions
increases expression

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]
ochratoxin A results in increased expression of CASP9 mRNA; ochratoxin A results in increased expression of CASP9 protein; ochratoxin A results in increased expression of CASP9 protein modified form

PMID:33905761 PMID:36397609

NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007

G

catalase

decreases expression
multiple interactions

ochratoxin A results in decreased expression of CAT mRNA; ochratoxin A results in decreased expression of CAT protein
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]

PMID:18547704 PMID:36281498

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

crystallin alpha B

increases expression

ochratoxin A results in increased expression of CRYAB mRNA

NCBI chr 9:39,638,505...39,643,530
Ensembl chr 9:39,638,506...39,643,530

G

cytochrome c, somatic

multiple interactions
increases expression

fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CYCS mRNA]

NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866

G

cytochrome P450 family 2 subfamily A member 19

decreases expression

ochratoxin A results in decreased expression of CYP2A6 mRNA

NCBI chr 6:49,056,579...49,064,111
Ensembl chr 6:49,056,578...49,064,107

G

defender against cell death 1

decreases expression

ochratoxin A results in decreased expression of DAD1 mRNA

NCBI chr 7:76,432,040...76,457,403
Ensembl chr 7:76,432,051...76,457,192

G

DNA methyltransferase 1

increases expression
multiple interactions

ochratoxin A results in increased expression of DNMT1 mRNA; ochratoxin A results in increased expression of DNMT1 protein
Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein]

PMID:29080797 PMID:30923867

NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844

G

DNA methyltransferase 3 alpha

increases expression

ochratoxin A results in increased expression of DNMT3A mRNA

PMID:29080797 PMID:30923867

NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087

G

glutamate-cysteine ligase catalytic subunit

decreases expression
multiple interactions

ochratoxin A results in decreased expression of GCLC mRNA
ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GCLC mRNA]

NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530

G

glomulin, FKBP associated protein

increases expression

ochratoxin A results in increased expression of GLMN mRNA

NCBI chr 4:124,773,957...124,813,336
Ensembl chr 4:124,773,980...124,813,335

G

glutathione peroxidase 1

decreases expression
multiple interactions

ochratoxin A results in decreased expression of GPX1 mRNA
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

glutathione peroxidase 4

decreases expression
multiple interactions

ochratoxin A results in decreased expression of GPX4 mRNA
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]

NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931

G

gasdermin D

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]

NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271

G

H2A.X variant histone

multiple interactions
increases expression

alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein]

PMID:30923867 PMID:32454083

NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084

G

hepatitis A virus cellular receptor 1

multiple interactions

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of HAVCR1 mRNA

NCBI chr16:66,162,318...66,208,868

G

histone deacetylase 1

multiple interactions
increases expression

Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein]
ochratoxin A results in increased expression of HDAC1 mRNA; ochratoxin A results in increased expression of HDAC1 protein

NCBI chr 6:88,749,611...88,785,220
Ensembl chr 6:88,749,634...88,785,411

G

heat shock protein 90 beta family member 1

increases expression
decreases expression

ochratoxin A results in increased expression of HSP90B1 mRNA
ochratoxin A results in decreased expression of HSP90B1 mRNA

NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991

G

heat shock protein family A (Hsp70) member 5

increases expression

ochratoxin A results in increased expression of HSPA5 mRNA; ochratoxin A results in increased expression of HSPA5 protein

NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894

G

heat shock protein family D (Hsp60) member 1

decreases expression

ochratoxin A results in decreased expression of HSPD1 mRNA

NCBI chr15:101,360,355...101,373,498
Ensembl chr15:101,360,094...101,373,526

G

inhibitor of DNA binding 2

decreases expression

ochratoxin A results in decreased expression of ID2 mRNA

NCBI chr 3:127,500,759...127,503,207
Ensembl chr 3:127,500,763...127,503,257

G

insulin like growth factor binding protein 2

increases expression

ochratoxin A results in increased expression of IGFBP2 mRNA

NCBI chr15:118,822,092...118,850,985
Ensembl chr15:118,822,047...118,850,976

G

interleukin 18

increases expression

ochratoxin A results in increased expression of IL18 protein

NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219

G

interleukin 1 alpha

multiple interactions

ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]

NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119

G

interleukin 2

decreases secretion

ochratoxin A results in decreased secretion of IL2 protein

NCBI chr 8:101,640,938...101,645,683
Ensembl chr 8:101,640,944...101,645,609

G

interleukin 4

increases expression

ochratoxin A results in increased expression of IL4 mRNA

NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365

G

interleukin 6

increases expression
multiple interactions

ochratoxin A results in increased expression of IL6 mRNA
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

Janus kinase 2

multiple interactions
increases phosphorylation

Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of JAK2 protein]

NCBI chr 1:216,849,744...217,002,310
Ensembl chr 1:216,848,689...217,002,148

G

lipocalin 2

multiple interactions

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of LCN2 mRNA

NCBI chr 1:268,609,975...268,614,651
Ensembl chr 1:268,609,887...268,614,644

G

glutathione S-transferase alpha M14

decreases expression
multiple interactions

ochratoxin A results in decreased expression of GSTA1 mRNA
ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GSTA1 mRNA]

NCBI chr 7:46,553,813...46,567,596

G

interleukin-1 beta-like

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

ochratoxin A results in increased phosphorylation of MAPK1 protein
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

PMID:28528741 PMID:28699257

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
ochratoxin A results in increased phosphorylation of MAPK3 protein

PMID:28528741 PMID:28699257

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

G

mechanistic target of rapamycin kinase

decreases phosphorylation

ochratoxin A results in decreased phosphorylation of MTOR protein

NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888

G

MYD88 innate immune signal transduction adaptor

multiple interactions

ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 protein]

NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109

G

MYG1 exonuclease

decreases expression

ochratoxin A results in decreased expression of PFDN5 mRNA

NCBI chr 5:18,512,637...18,516,928
Ensembl chr 5:18,512,697...18,517,174

G

nei like DNA glycosylase 1

decreases expression
multiple interactions

ochratoxin A results in decreased expression of NEIL1 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]

NCBI chr 7:58,261,761...58,269,001
Ensembl chr 7:58,261,769...58,268,522

G

nei like DNA glycosylase 3

multiple interactions
decreases expression

alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]

NCBI chr15:39,416,073...39,632,313
Ensembl chr15:39,581,856...39,632,308

G

NFE2 like bZIP transcription factor 2

decreases activity
multiple interactions
decreases expression

ochratoxin A results in decreased activity of NFE2L2 protein
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein]; ochratoxin A inhibits the reaction [sulforaphane affects the localization of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased expression of NFE2L2 mRNA]
ochratoxin A results in decreased expression of NFE2L2 mRNA

PMID:18547363 PMID:18547704 PMID:28710020

NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183

G

NLR family pyrin domain containing 3

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]

NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228

G

nitric oxide synthase 2

increases expression
multiple interactions

ochratoxin A results in increased expression of INOS mRNA
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of INOS mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of INOS mRNA]

NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146

G

nucleophosmin 1

increases expression

ochratoxin A results in increased expression of NPM1 mRNA

NCBI chr16:52,767,263...52,781,862
Ensembl chr16:52,765,298...52,781,771

G

netrin 1

multiple interactions
increases expression

fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of NTN1 mRNA]

NCBI chr12:54,089,444...54,292,191
Ensembl chr12:54,089,472...54,292,193

G

8-oxoguanine DNA glycosylase

decreases expression
multiple interactions

ochratoxin A results in decreased expression of OGG1 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]

NCBI chr13:66,038,669...66,045,478

G

poly(ADP-ribose) polymerase 1

increases cleavage
increases expression
multiple interactions

ochratoxin A results in increased cleavage of PARP1 protein
ochratoxin A results in increased expression of PARP1 protein
3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]

PMID:30287338 PMID:32454083

NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196

G

phosphoenolpyruvate carboxykinase 1

decreases expression

ochratoxin A results in decreased expression of PCK1 mRNA; ochratoxin A results in decreased expression of PCK1 protein

NCBI chr17:57,930,507...57,936,523
Ensembl chr17:57,930,432...57,936,522

G

proliferating cell nuclear antigen

decreases expression

ochratoxin A results in decreased expression of PCNA protein

NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744

G

peptidylprolyl isomerase A

increases expression

ochratoxin A results in increased expression of PPIA mRNA

NCBI chr18:50,563,130...50,566,857

G

peroxiredoxin 1

decreases expression

ochratoxin A results in decreased expression of PRDX1 mRNA

NCBI chr 6:165,847,390...165,859,918
Ensembl chr 6:165,824,395...165,861,442

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PTGS2 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of PTGS2 mRNA]

NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884

G

prothymosin alpha

decreases expression

ochratoxin A results in decreased expression of PTMA mRNA

NCBI chr15:132,353,763...132,361,442
Ensembl chr15:132,355,655...132,361,435

G

PYD and CARD domain containing

increases expression
multiple interactions

ochratoxin A results in increased expression of PYCARD protein
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]

NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786

G

RAD51 recombinase

increases expression

ochratoxin A results in increased expression of RAD51 protein

NCBI chr 1:130,592,414...130,640,326
Ensembl chr 1:130,586,665...130,640,136

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]

NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469

G

replication protein A2

increases expression

ochratoxin A results in increased expression of RPA2 protein

NCBI chr 6:85,032,604...85,045,899
Ensembl chr 6:85,031,582...85,045,915

G

ribosomal protein S5

increases expression

ochratoxin A results in increased expression of RPS5 mRNA

NCBI chr 6:62,967,955...62,974,353
Ensembl chr 6:62,967,994...62,974,350

G

suppressor of cytokine signaling 3

increases expression
multiple interactions

ochratoxin A results in increased expression of SOCS3 mRNA; ochratoxin A results in increased expression of SOCS3 protein
Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 mRNA]; Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 protein]

NCBI chr12:3,643,832...3,647,015
Ensembl chr12:3,643,929...3,647,009

G

superoxide dismutase 1

decreases activity

ochratoxin A results in decreased activity of SOD1 protein

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

secreted phosphoprotein 1

multiple interactions
increases expression

fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of SPP1 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of SPP1 mRNA]

NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340

G

sequestosome 1

multiple interactions
decreases expression

Chloroquine inhibits the reaction [ochratoxin A results in decreased expression of SQSTM1 protein]

NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of STAT3 protein]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein]

NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,992

G

small ubiquitin like modifier 1

decreases expression

ochratoxin A results in decreased expression of SUMO1 mRNA

NCBI chr15:105,820,237...105,850,099
Ensembl chr15:105,818,858...105,850,233

G

transforming growth factor beta 1

increases expression
multiple interactions

ochratoxin A results in increased expression of TGFB1 mRNA
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; sulforaphane inhibits the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]

NCBI chr 6:49,332,169...49,348,642
Ensembl chr 6:49,332,173...49,349,046

G

TIMP metallopeptidase inhibitor 2

increases expression

ochratoxin A results in increased expression of TIMP2 mRNA

NCBI chr12:3,254,794...3,300,835
Ensembl chr12:3,254,493...3,300,834

G

tight junction protein 1

affects localization

ochratoxin A affects the localization of TJP1 protein

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

toll like receptor 4

multiple interactions

ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]

NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970

G

tumor necrosis factor

multiple interactions
increases secretion

ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
ochratoxin A results in increased secretion of TNF protein

PMID:28528741 PMID:28699257

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

tumor protein p53

multiple interactions
increases expression

NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein]

PMID:28710020 PMID:32454083

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

G

XPA, DNA damage recognition and repair factor

decreases expression

ochratoxin A results in decreased expression of XPA mRNA

NCBI chr 1:239,532,331...239,568,589
Ensembl chr 1:239,532,272...239,568,570

G

X-ray repair cross complementing 1

increases expression

ochratoxin A results in increased expression of XRCC1 protein

NCBI chr 6:50,403,691...50,425,730
Ensembl chr 6:50,403,689...50,425,729

ochratoxin B

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

NFE2 like bZIP transcription factor 2

decreases activity

ochratoxin B results in decreased activity of NFE2L2 protein

NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183

oxytetracycline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier organic anion transporter family member 1A2

multiple interactions
increases uptake

Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
SLCO1A2 protein results in increased uptake of Oxytetracycline

NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730

p-xylene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity
multiple interactions
affects response to substance

4-xylene results in increased activity of CASP3 protein
aspartyl-glutamyl-valyl-aspartal inhibits the reaction [4-xylene results in increased activity of CASP3 protein]
CASP3 protein affects the susceptibility to 4-xylene

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

catalase

multiple interactions

CAT protein inhibits the reaction [4-xylene results in increased secretion of Malondialdehyde]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

cytochrome P450 family 2 subfamily E member 1

increases activity
multiple interactions

4-xylene results in increased activity of CYP2E1 protein
Disulfiram inhibits the reaction [4-xylene results in increased activity of CYP2E1 protein]

NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,817

phorbol 13-acetate 12-myristate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-X-C motif chemokine ligand 8

multiple interactions

[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of CXCL8 protein

NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861

G

endothelin 1

multiple interactions
increases expression

Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EDN1 protein]

NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348

G

mitogen-activated protein kinase 1

increases phosphorylation

Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 3

increases phosphorylation

Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

G

mitogen-activated protein kinase 9

increases phosphorylation

Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein

NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,376...78,399,100

G

peroxisome proliferator activated receptor alpha

decreases expression
multiple interactions

Tetradecanoylphorbol Acetate results in decreased expression of PPARA; Tetradecanoylphorbol Acetate results in decreased expression of PPARA protein
calphostin C promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of PPARA]; Tetradecanoylphorbol Acetate inhibits the reaction [Clofibrate results in increased expression of PPARA]

PMID:17105827 PMID:20568414

NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239

G

protein kinase C beta

decreases phosphorylation

Tetradecanoylphorbol Acetate results in decreased phosphorylation of PRKCB protein

NCBI chr 3:21,995,227...22,383,628
Ensembl chr 3:21,995,231...22,383,264

G

protein kinase C delta

increases phosphorylation

Tetradecanoylphorbol Acetate results in increased phosphorylation of PRKCD protein

NCBI chr13:35,290,835...35,323,245
Ensembl chr13:35,290,610...35,323,356

G

selectin E

increases expression

Tetradecanoylphorbol Acetate results in increased expression of SELE protein

NCBI chr 4:81,289,061...81,299,657

G

selectin P

increases expression

Tetradecanoylphorbol Acetate results in increased expression of SELP protein

NCBI chr 4:81,376,804...81,401,240
Ensembl chr 4:81,365,740...81,399,955

G

vascular cell adhesion molecule 1

increases expression

Tetradecanoylphorbol Acetate results in increased expression of VCAM1 protein

NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222

potassium chromate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glyceraldehyde-3-phosphate dehydrogenase

decreases activity

potassium chromate(VI) results in decreased activity of GAPDH protein

NCBI chr 5:64,129,678...64,135,194
Ensembl chr 5:64,129,679...64,133,991

salubrinal

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

eukaryotic translation initiation factor 2A

increases phosphorylation

salubrinal results in increased phosphorylation of EIF2A protein

NCBI chr13:90,761,453...90,804,274
Ensembl chr13:90,761,465...90,804,274

sodium arsenite

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases degradation
multiple interactions
decreases expression

sodium arsenite results in increased degradation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of AKT1 protein]; sodium arsenite results in decreased expression of and results in increased phosphorylation of AKT1 protein; Wortmannin inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
sodium arsenite results in decreased expression of AKT1 protein

PMID:12760830 PMID:16239170

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
increases expression

bisindolylmaleimide I inhibits the reaction [sodium arsenite results in increased expression of HIF1A mRNA]; Go 6976 inhibits the reaction [sodium arsenite results in increased expression of HIF1A mRNA]
sodium arsenite results in increased expression of HIF1A mRNA; sodium arsenite results in increased expression of HIF1A protein

NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845

G

mitogen-activated protein kinase 6

increases expression

sodium arsenite results in increased expression of MAPK6 protein

NCBI chr 1:119,725,026...119,770,988
Ensembl chr 1:119,725,029...119,771,312

G

nitric oxide synthase 3

multiple interactions
increases degradation
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased phosphorylation of NOS3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of NOS3 protein]; sodium arsenite results in increased phosphorylation of and results in decreased activity of NOS3 protein; Wortmannin inhibits the reaction [sodium arsenite results in increased phosphorylation of NOS3 protein]
sodium arsenite results in decreased expression of NOS3 protein

NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943

G

protein kinase cAMP-activated catalytic subunit alpha

decreases expression

sodium arsenite results in decreased expression of PRKACA protein

NCBI chr 2:65,074,876...65,095,564
Ensembl chr 2:65,074,870...65,095,551

G

protein kinase C delta

increases phosphorylation

sodium arsenite results in increased phosphorylation of PRKCD protein

NCBI chr13:35,290,835...35,323,245
Ensembl chr13:35,290,610...35,323,356

G

ribosomal protein S6 kinase A1

decreases expression

sodium arsenite results in decreased expression of RPS6KA1 protein

NCBI chr 6:83,905,124...83,947,189
Ensembl chr 6:83,905,077...83,950,963

G

superoxide dismutase 1

multiple interactions
increases activity

[sodium arsenite results in increased activity of SOD1 protein] which results in increased abundance of Hydrogen Peroxide

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

tumor protein p53

increases expression

sodium arsenite results in increased expression of TP53

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

G

vascular endothelial growth factor A

increases expression
multiple interactions

sodium arsenite results in increased expression of VEGFA mRNA
bisindolylmaleimide I inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; R 59949 promotes the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; sodium arsenite results in increased expression of and results in increased secretion of VEGFA protein

NCBI chr 7:38,746,393...38,762,282
Ensembl chr 7:38,746,052...38,761,366

tetracycline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier organic anion transporter family member 1A2

increases uptake
multiple interactions

SLCO1A2 protein results in increased uptake of Tetracycline
Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]

NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730

toluene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity
affects response to substance
multiple interactions

Toluene results in increased activity of CASP3 protein
CASP3 protein affects the susceptibility to Toluene
aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Toluene results in increased activity of CASP3 protein]

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

catalase

multiple interactions

CAT protein inhibits the reaction [Toluene results in increased secretion of Malondialdehyde]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

cytochrome P450 family 2 subfamily E member 1

multiple interactions
increases activity

Disulfiram inhibits the reaction [Toluene results in increased activity of CYP2E1 protein]

NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,817

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	5052
role	5044
biological role	5016
aetiopathogenetic role	4604
carcinogenic agent	251
(trichloromethyl)benzene	0
1,1-dichloroethene	0
1,1-dimethylhydrazine	0
1,2-dibromoethane	0
1,2-dimethylhydrazine	0
1,2-naphthoquinone	0
1,3-benzothiazole-2-thiol +	1
1,4-dioxane	0
1-methylnaphthalene	0
1-nitropyrene	0
19-bromoaplysiatoxin	0
2,4,6-trichlorophenol	0
2,6-dichlorobenzoquinone	0
2,6-dimethylaniline +	0
2-(acetoxyamino)-3-methylimidazo[4,5-f]quinoline	0
2-acetamidofluorene +	0
2-aminoacetyl fluoride	0
2-ethylhexyl sulfate	0
2-hydroxy-17beta-estradiol +	0
2-naphthylamine +	0
2-nitroanisole	0
2-nitrofluorene	0
2-nitropropane	0
2-nitrotoluene	0
3,6-diamino-10-methylacridinium chloride +	0
3,6-diamino-10-methylacridinium chloride.HCl +	0
3,6-diaminoacridine	0
3,6-diaminoacridine dihydrochloride +	0
3,6-diaminoacridine monohydrochloride +	0
3-methyl-3H-imidazo[4,5-f]quinolin-2-amine	0
3-methyl-4'-dimethylaminoazobenzene	0
3-methylcholanthrene +	0
4'-(4-fluorophenyl)acetanilide	0
4,4'-diaminoazobenzene	0
4,4'-diaminodiphenylmethane	0
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol	0
4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid	0
4-hydroxy-8-methoxyquinaldic acid	0
4-hydroxyestrone +	0
4-methylcatechol +	0
4-methylimidazole	0
4-nitroquinoline N-oxide	0
4-vinylcyclohexene dioxide	0
5-methoxyindole-3-acetic acid	0
6-propyl-2-thiouracil +	1
7,12-dimethyltetraphene	1
Aroclor 1254	0
DDT +	0
DL-ethionine	0
GW 501516 +	0
ICR 340	0
L-ethionine +	0
MeIQx +	0
N,N-bis(2-hydroxypropyl)nitrosamine +	0
N-(2,6-diethylphenyl)-2-chloroacetamide	0
N-2-fluorenylphthalamic acid	0
N-acetoxy-2-acetamidofluorene	0
N-butyl-N-(3-carboxypropyl)nitrosamine	0
N-butyl-N-(4-hydroxybutyl)nitrosamine +	0
N-ethyl-N-(2-hydroxyethyl)nitrosamine	0
N-ethyl-N-nitrosourea	0
N-hydroxy-4-aminobiphenyl	0
N-hydroxy-MeIQx	0
N-hydroxy-PhIP	0
N-methyl-N-nitrosourea	0
N-methyl-N-pentylnitrosamine	0
N-nitrobis(2-hydroxypropyl)amine	0
N-nitroso-N-methyl-4-aminobutyric acid	0
N-nitrosodiethylamine +	0
N-nitrosomorpholine	0
N-nitrosopiperidine	0
N-nitrososarcosine	0
PhIP +	0
Pontamine sky blue 5B	0
Pontamine sky blue 5B (acid form)	0
Sudan III	0
Sudan IV	0
acetaldehyde +	1
acid red 26	0
acriflavinium chloride	0
acriflavinium monochloride	0
acrylamide	6
acrylonitrile +	0
aflatoxin B1 +	0
aflatoxin Q1	0
aplysiatoxin	0
aristolochic acid A +	6
aristolochic acid B	0
aristolochic acid C	0
aristolochic acid D	0
aristolochic acids +	6
azathioprine	0
benzene +	81
benzidine	0
benzo[a]pyrene +	25
benzo[e]pyrene	0
benzoyl chloride +	0
beryllium atom +	0
beryllium dichloride	0
beryllium oxide	0
biphenyl-4-amine +	0
bis(2-chloroethyl) sulfide	94
bis(chloromethyl) ether	0
bromoethane	0
busulfan	0
buta-1,3-diene +	0
cadmium nitrate +	17
cadmium nitrate tetrahydrate	0
chlorambucil	0
chlorendic acid	0
chloroethene	0
chloroform +	0
cobalt(2+) sulfate heptahydrate	0
colibactin	0
cyclophosphamide +	7
cyclophosphamide hydrate	0
cyclosporin A +	10
dacarbazine +	0
debromoaplysiatoxin	0
diazomethane	0
dichloromethane	0
dieldrin	0
diethyl sulfate	0
diethylstilbestrol +	0
dihydrosterigmatocystin +	0
estragole	0
ethyl methanesulfonate	0
formaldehyde +	0
fumonisin B1	48
fumonisin B2	0
furan +	0
hexachlorobenzene	7
hexachloroethane	0
hydroquinone +	0
iron(III) nitrilotriacetate	0
lead chromate	0
malachite green	0
melphalan	0
methapyrilene +	0
methapyrilene hydrochloride	0
methyl methanesulfonate	0
methylarsonous acid	0
musk xylene	0
nafenopin	0
naphthalene +	3
naphthalene-1,5-diamine	0
nickel subsulfide +	0
nitrilotriacetic acid +	0
nitrosobis(2-oxopropyl)amine	0
nitrosocarbaryl	0
o-toluidine +	0
ochratoxin A +	76
patulin +	0
perfluorooctanoic acid	0
phenazopyridine	0
phenazopyridine hydrochloride	0
phorbol 13-acetate 12-myristate	11
phosphane +	0
polycyclic arene +	35
potassium chromate	1
rac-1,2-dichloropropane +	0
riddelliine +	0
riddelliine N-oxide	0
rosanilin +	0
rosanilin free base	0
semustine	0
sodium arsenite	10
sodium chromate	0
sodium dihydrogen arsenate	0
sodium nitrilotriacetate	0
sulfamethazine +	0
tannic acid	0
tetraconazole	0
thiamethoxam +	0
toxaphene	0
trichloroacetic acid +	0
trypan blue	0
versicolorin A +	0

paths to the root